Nuclear Cardiology

Single photon computed tomography (SPECT) and positron emission tomography (PET) molecular imaging are used as primary cardiac imaging modalities to evaluate the function of the heart. It uses radioactive isotopes attached to sugars that are metabolized by cardiomyocytes. This creates an image of the metabolic activity of the heart and shows areas of ischemia or infarct. Other radiotracers can image the heart to diagnosis cardiac amyloidosis and sarcoidosis. 

Rob deKemp, PhD, FASNC, University of Ottawa, Canada, explains new nuclear cardiac imaging dose lowering techniques for PET and SPECT.

How to achieve much lower radiation doses in cardiac nuclear imaging

The radiation doses associated with CT have decreased significantly, leaving nuclear cardiology as the modality with the highest doses in all of cardiac imaging. Rob deKemp, PhD, talked to us about some of the many ways imagers can work to address this issue.

Jamie Bourque, MD, discusses fluorodeoxyglucose (FDG) and its growing use cases in cardiac PET imaging He discussed the radiotracer in sessions at ASNC 2023. #ASNC #ASNC23 #ASNC2023

The expanding scope of FDG-PET in nuclear cardiac imaging

Jamie Bourque, MD, spoke to Cardiovascular Business about the growing number of ways FDG-PET scans are being used in cardiology. This includes evaluating inflammation, tracking EP device infections and much more. 

Robert Hendel, MD, Tulane University and former ASNC president, explains the pressing business aspects of nuclear cardiology and why ASNC included business management sessions at its 2023 annual meeting. #ASNC #ASNC23 #ASNC2023

Business considerations in the modern nuclear cardiology practice

Robert Hendel, MD, discussed everything from declining reimbursements in cardiology to prior authorization policies in an exclusive new interview. 

Department of Justice DOJ

Cardiologists at heart of alleged kickback scheme—imaging provider, CEO to pay $85M to settle

The allegations revolve around payments referring cardiologists received to supervise PET scans from March 2014 to May 2023.

Timothy Bateman, MD, co-director, cardiovascular radiologic imaging program, Saint Luke's Mid America Heart Institute, professor of medicine at the University of Missouri-Kansas City School of Medicine, and an ASNC past-president, is one of the authors on the AURORA study. He spoke with Cardiovascular Business about the study and what it is like to work with flurpiridaz.

Flurpiridaz will have a major impact on cardiac PET and nuclear imaging

The new radiotracer flurpiridaz is poised to make a major impact on nuclear cardiology. Timothy Bateman, MD, co-director of the cardiovascular radiologic imaging program at Saint Luke's Mid America Heart Institute, shared details on the tracer in a new interview. 

Video of ASNC President Mouaz Al-Mallah, MD, explaining some long-COVID cardiac symptoms might be due to coronary microvascular dysfunction. He was part of a recent study that used PET top assess myocardial perfusion that found there is impaired microvascular flow in long-COVID patients.

PET imaging helps assess coronary microvascular dysfunction in long COVID patients

Researchers noted that patients appeared to have myocarditis at first, but a closer examination revealed it was something else entirely. 

doctor in handcuffs after being arrested

Cardiologist to pay $6.5M after trading kickbacks for imaging referrals in complex fraud scheme

In addition to the hefty fine, the New York physician has agreed to relinquish ownership of his cardiology practice after exchanging kickbacks for PET and SPECT referrals for more than a decade.

Video interview with ASNC President President Mouaz Al-Mallah, MD, who explains why nuclear cardiology needs to upgrade its technology to be competitive. #ASNC #ASNC2023 #ASNC23

Previewing ASNC 2023: Why nuclear cardiology needs to evolve

ASNC President President Mouaz Al-Mallah, MD, said nuclear cardiology needs to upgrade old imaging systems and embrace new technology to deliver better value for patients. 

Around the web

GE HealthCare said the price of iodine contrast increased by more than 200% between 2017 to 2023. Will new Chinese tariffs drive costs even higher?

Several key trends were evident at the Radiological Society of North America 2024 meeting, including new CT and MR technology and evolving adoption of artificial intelligence.